Lupin, KPI Global Infrastructure and PTC India to see some action today

Lupin Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500257 | NSE: LUPIN

09 Feb 2022 Evaluate

Lupin has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials to market a generic equivalent of Brovana Inhalation Solution, 15 mcg /2 ml of Sunovion Pharmaceuticals Inc. (Sunovion).

KPI Global Infrastructure has received the biggest single order for executing solar power project of 25 MWdc capacity from Greenlab Diamonds, Surat under 'Captive Power Producer (CPP)' segment of the Company. Earlier, the company had received order for executing solar power project of 2 MWdc capacity from Shabnam Petrofils, Surat under Captive Power Producer segment of the Company.

PTC India has bagged new contracts worth Rs 10.08 crore under consulting services. As per the contracts, the company will provide services to Madhya Pradesh Industrial Development Corporation (MPIDC).

IDFC First Bank has raised Rs 1,500 crore through private placement of Unsecured, Subordinated, Rated, Listed, Non-Convertible, Fully Paid-Up, Taxable, Redeemable Basel III Compliant Tier 2 Bonds (in the nature of Debentures) for a face value of Rs 1 crore each. The Bonds shall be redeemed in accordance with the terms of issue on its original maturity of 10 years, however, a Call Option may be exercised at the sole discretion of the Bank after completion of 5 years from the date of allotment and yearly thereafter, and subject to fulfilment of extant regulatory provisions.

Thermax has executed Share Subscription Agreement with Exactspace Technologies and its Promoters and Shareholders Agreement with Exactspace, its Promoters and Shell India Markets (Existing Investor). The investment will result in the company holding up to 15.17% of the share capital of Exactspace. The company proposes to provide end to end asset support to customers and increase its share of service offerings by collaborating with Exactspace as IoT solution partner.

Ugro Capital has raised its first impact focused debt investment of Rs 138 crore from funds managed/ advised by Switzerland based impact investor responsAbility. The transaction was structured in two legs - in the first leg, an Rs 31 crore equivalent USD-denominated ECB was raised which was followed by Rs denominated NCDs totalling Rs 107 crore in the second leg.

Amrapali Industries’ board has approved the incorporation of a wholly owned subsidiary of the company namely Amrapali Industries Global lFSC (WOS) by subscribing 1,50,000 shares of Rs 10 each in the paid-up share capital of the Proposed Company.

Lupin Share Price

2476.10 77.40 (3.23%)

03-Jul-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1904.65
Dr. Reddys Labs.	1374.55
Cipla	1458.45
Zydus Lifesciences	1141.00
Lupin	2476.10
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.